These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 37896191)

  • 1. Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.
    Domingues C; Jarak I; Veiga F; Dourado M; Figueiras A
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nanotechnology-based formulations in pediatric populations.
    Yellepeddi VK; Joseph A; Nance E
    Adv Drug Deliv Rev; 2019; 151-152():44-55. PubMed ID: 31494124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them.
    Rousseau CF; Mačiulaitis R; Śladowski D; Narayanan G
    Front Med (Lausanne); 2018; 5():158. PubMed ID: 29911104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pediatric studies initiative: after 15 years have we reached the limits of the law?
    Milne CP; Davis J
    Clin Ther; 2014 Feb; 36(2):156-62. PubMed ID: 24529287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?
    Nieto González N; Obinu A; Rassu G; Giunchedi P; Gavini E
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34066953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing Pressing Needs in the Development of Advanced Therapies.
    Morrow D; Ussi A; Migliaccio G
    Front Bioeng Biotechnol; 2017; 5():55. PubMed ID: 28993805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
    Beattie S;
    Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges with advanced therapy medicinal products and how to meet them.
    ; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
    Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European regulatory tools for advanced therapy medicinal products.
    Flory E; Reinhardt J
    Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.